- CH₣311.46bn
- CH₣337.55bn
- CH₣61.52bn
Roche to unveil lung, breast cancer data at ESMO 2026
Brief: Roche To Present Late-Stage Lung And Breast Cancer Data At ESMO 2026
Biotech co Alector rises after premium-priced $75 mln stock sale
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Roche Receives FDA's Approval For Its Enspryng, A First-In-Class IL-6R Inhibitor
Biocon settles Roche's US patent lawsuit over proposed breast-cancer drug copy
Factbox: Major drugmakers turn to China for licensing deals
Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics
Street View: Merck eye disease drug matches Roche's therapy in study, analysts cautious
Europe Research Roundup: ABB, Nexans, Volution Group
Swiss stocks - Factors to watch on October 12
Brief: Roche Presents New Phase Iii One-Year Data For Vamikibart In Uveitic Macular Edema
Brief: FDA Approves Roche’S Tecentriq
Brief: Us FDA Approves Tecentriq With Chemotherapy For Stage III DMMR Colon Cancer
Zealand Pharma slides after obesity drug data
Zealand, Roche's obesity drug helps patients lose up to 9.2% weight in mid-stage trial
Brief: Zealand Pharma Announces Positive Phase 2 Zupreme-2 Topline Results For Amylin Analog Petrelintide In People With Overweight Or Obesity And Type 2 Diabetes
Brief: Roche Delivers Laboratory Equipment To Support Ebola Testing In Drc
Factbox: Global healthcare companies invest billions to boost US presence